Advances in pharmacotherapy for cardiac amyloidosis

References

• Fine NM, Davis MK, Anderson K, et al. Canadian cardiovascular society/canadian heart failure society joint position statement on the evaluation and management of patients with cardiac amyloidosis. Can J Cardiol. 2020;36(3): 322–334.
   PubMed Web of Science ®Google Scholar
• Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification international society of amyloidosis 2016 nomenclature guidelines. Amyloid. 2016;23(4):209–213.
   PubMed Web of Science ®Google Scholar
• WHO-IUIS Nomenclature Sub-committee. Nomenclature of amyloid and amyloidosis. Bull World Health Organ. 1993;71:105–112.
   PubMed Web of Science ®Google Scholar
• Leung N, Nasr SH, Sethi S. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood. 2012;120(16):3206–3213.
   PubMed Web of Science ®Google Scholar
• Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc. 2015;24:343–350.
   Google Scholar
• Banypersad SM, Moon JC, Whelan C, et al. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1:e000364.
   PubMed Web of Science ®Google Scholar
• Falk RH, Alexander KM, Liao R, et al. AL (lightchain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68(12):1323–1341.
   PubMed Web of Science ®Google Scholar
• Milani P, Basset M, Russo F, et al. Patients with lightchain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017;130(5):625–631.
   PubMed Web of Science ®Google Scholar
• González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–2594.
   PubMed Web of Science ®Google Scholar
• Nienhuis HLA, Bijzet J, Hazenberg BPC. The prevalence and management of systemic amyloidosis in Western countries. Kidney Dis (Basel, Switzerland). 2016;2:10–19.
   PubMed Web of Science ®Google Scholar
• Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014–1020.
   PubMed Web of Science ®Google Scholar
• Gillmore JD. A new staging system from cardiac transthyretin amyloidosis. Eur Heart J. 2018;39:2799–2806.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clinic Oncol. 2012;30:989–995.
   PubMed Web of Science ®Google Scholar
• Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95:535–537.
   PubMed Web of Science ®Google Scholar
• Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442–1448.
   PubMed Web of Science ®Google Scholar
• Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 2014;7(3):552–562.
   PubMed Web of Science ®Google Scholar
• Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc- 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–1084.
   PubMed Web of Science ®Google Scholar
• Leone O, Veinot JP, Angelini A, et al. 2011 consensus statement on endomyocardial biopsy from the association for European cardiovascular pathology and the society for cardiovascular pathology. Cardiovasc Pathol. 2012;21(4):245–274.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317–2325.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336(17):1202–1207.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083–1093.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998;91(10):3662–3670.
   PubMed Web of Science ®Google Scholar
• Oliva L, Orfanelli U, Resnati M, et al. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood. 2017;129(15):2132–2142.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Lachmann HJ, Offer M, et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008;93(2):295–298.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031–1037.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391–4394.
   PubMed Web of Science ®Google Scholar
• Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387–4390.
   PubMed Web of Science ®Google Scholar
• Shah G, Kaul E, Fallo S, et al. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients. Clin Ther. 2013;35(10):1614–1620.
   PubMed Web of Science ®Google Scholar
• Palladini G, Sachchithanantham S, Milani P, et al. A European Collaborative Study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5): 612–615.
   PubMed Web of Science ®Google Scholar
• Sperry BW, Ikram A, Hachamovitch R, et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol. 2016;67(25):2941–2948.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Scott EC, Liedtke M, et al. Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Blood. 2016;128(22):645.
   Web of Science ®Google Scholar
• Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597–605.
   PubMed Web of Science ®Google Scholar
• Study of dexamethasone plus IXAZOMIB (MLN 9708) or physicians choice of treatment in relapsed or refractory systemic light chain (AL) amyloidosis. 2020 [cited 2020 May 10]. Available at: https://ClinicalTrials.gov/show/NCT01659658
   Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22–32.
   PubMed Web of Science ®Google Scholar
• Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301–305.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–1571.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109(2):465–470.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492–496.
   PubMed Web of Science ®Google Scholar
• Mahmood S, Venner CP, Sachchithanantham S, et al. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. Br J Haematol. 2014;166(6):842–848.
   PubMed Web of Science ®Google Scholar
• Hegenbart U, Bochtler T, Benner A, et al. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. Haematologica. 2017;102(8):1424–1431.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Buadi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin lightchain amyloidosis. Blood. 2012;119(23):5397–5404.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Shelton AC, Lo S, et al. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016;128(8):1059–1062.
   PubMed Web of Science ®Google Scholar
• Palladini G, Milani P, Foli A, et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood. 2017;129(15):2120–2123.
   PubMed Web of Science ®Google Scholar
• Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130(7):900–902.
   PubMed Web of Science ®Google Scholar
• Daratumumab for the treatment of patients with AL amyloidosis. 2020 [cited 2020 May 10]. Available at: https://ClinicalTrials.gov/show/NCT02841033
   Google Scholar
• Daratumumab therapy for patients with refractory or relapsed AL amyloidosis. 2020 [cited 2020 May 10]. Available at: https://ClinicalTrials.gov/show/NCT02816476
   Google Scholar
• A study to evaluate the efficacy and safety of daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared to CyBorD alone in newly diagnosed systemic amyloid light-chain (AL) amyloidosis. 2020 [cited 2020 May 10]. Available at: https://ClinicalTrials.gov/show/NCT03201965
   Google Scholar
• Wall JS, Kennel SJ, Williams A, et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One. 2012;7(12):e52686.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Landau H, Comenzo RL, et al. First-inhuman phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 2016;34(10):1097–1103.
   PubMed Web of Science ®Google Scholar
• Gertz M, Comenzo R, Landau H, et al. NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion cohort of a phase 1/2 study. Blood. 2016;128(22):644.
   Web of Science ®Google Scholar
• Edwards CV, Gould J, Langer AL, et al. Final analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with relapsed or refractory AL amyloidosis. Blood. 2017;130(Suppl. 1):509.
   Google Scholar
• Bhutani DL, Leng S, Eisenberger A, et al. Improvement in global longitudinal strain (GLS) correlates with NT-Probnp response in patients with cardiac amyloidosis treated on a phase 1b study of antiamyloid Mab Cael-101. Blood. 2018;121(Suppl. 1):958.
   Google Scholar
• Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015;373(12):1106–1114.
   PubMed Web of Science ®Google Scholar
• Richards DB, Cookson LM, Barton SV, et al. Repeat doses antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Sci Transl Med. 2018 Jan 3;10(422):eaan3128.
   PubMed Web of Science ®Google Scholar
• Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve. 2013;47(2):157–162.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012;78(9):637–643.
   PubMed Web of Science ®Google Scholar
• Hammarstrom P, Wiseman RL, Powers ET, et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003;299(5607):713–716.
   PubMed Web of Science ®Google Scholar
• Miroy GJ, Lai Z, Lashuel HA, et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A. 1996;93(26):15051–15056.
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–2667.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006;13(4):236–249.
   PubMed Web of Science ®Google Scholar
• Castano A, Helmke S, Alvarez J, et al. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail. 2012;18(6):315–319.
   PubMedGoogle Scholar
• Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–792.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802–2814.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Grogan DR, Judge DP, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015;8(3):519–526.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016.
   PubMed Web of Science ®Google Scholar
• Lozeron P, Theaudin M, Mincheva Z, et al. French Network for FAP (CORNAMYL). Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013;20(12):1539–1545.
   PubMed Web of Science ®Google Scholar
• Merlini G, Plante-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6(6):1011–1020.
   PubMed Web of Science ®Google Scholar
• Barroso FA, Judge DP, Ebede B, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24(3):194–204.
   PubMed Web of Science ®Google Scholar
• Cortese A, Vita G, Luigetti M, et al. Monitoring effectiveness and safety of tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol. 2016;263(5):916–924.
   PubMed Web of Science ®Google Scholar
• Planté-Bordeneuve V, Gorram F, Salhi H, et al. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol. 2017;264:268–276.
   PubMed Web of Science ®Google Scholar
• Damy T, Judge DP, Kristen AV, et al. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015;8(2):117–127.
   PubMed Web of Science ®Google Scholar
• Ferreira N, Cardoso I, Domingues MR, et al. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett. 2009;583(22):3569–3576.
   PubMed Web of Science ®Google Scholar
• Ferreira N, Saraiva MJ, Almeida MR. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: “in vivo” evidence from FAP mice models. PLoS One. 2012;7(1):e29933.
   PubMed Web of Science ®Google Scholar
• Ehrnhoefer DE, Bieschke J, Boeddrich A, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 2008;15(6):558–566.
   PubMed Web of Science ®Google Scholar
• Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol. 2012;101(10):805–813.
   PubMed Web of Science ®Google Scholar
• Aus Dem Siepen F, Buss SJ, Andre F, et al. Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. Clin Res Cardiol. 2015;104(8):640–647.
   PubMed Web of Science ®Google Scholar
• Hunstein W. Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood. 2007;110(6):2216.
   PubMed Web of Science ®Google Scholar
• Mereles D, Wanker EE, Katus HA. Therapy effects of green tea in a patient with systemic light-chain amyloidosis. Clin Res Cardiol. 2008;97(5):341–344.
   PubMed Web of Science ®Google Scholar
• Mereles D, Buss SJ, Hardt SE, et al. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol. 2010;99(8):483–490.
   PubMed Web of Science ®Google Scholar
• A trial for the treatment of cardiac AL-amyloidosis with the green tea compound epigallocatechin-3-gallate (TAME-AL). 2020 [cited 2020 May 10]. Available at: https://ClinicalTrials.gov/show/NCT02015312
   Google Scholar
• Penchala SC, Connelly S, Wang Y, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A. 2013;110(24):9992–9997.
   PubMed Web of Science ®Google Scholar
• Judge DP, Falk RH, Maurer MS, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74:285–295.
   PubMed Web of Science ®Google Scholar
• Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002;1:347–355.
   PubMed Web of Science ®Google Scholar
• Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019;70(1):307–321.
   PubMedGoogle Scholar
• Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31.
   PubMed Web of Science ®Google Scholar
• Bumcrot D, Manoharan M, Koteliansky V, et al. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2(12):711–719.
   PubMed Web of Science ®Google Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173–178.
   PubMed Web of Science ®Google Scholar
• Alnylam Pharmaceuticals Inc. Summary of product characteristics. European Medicines Agency, 2018. 2020 [cited 2020 May 10]. Available at: https://www.ema.europa.eu/en/documents/product-information/onpattro-epar-product-information_en.pdf
   Google Scholar
• Alnylam Pharmaceuticals Inc. Prescribing information for onpattro. 2020 [cited 2020 May 10]. Available at: http://www.alnylam.com/wp-content/uploads/2018/08/ONPATTRO-Prescribing-.
   Google Scholar
• Hayashi Y, Mori Y, Yamashita S, et al. Potential use of lactosylated dendrimer (G3)/alpha-cyclodextrin conjugates as hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy. Mol Pharm. 2012;9(6):1645–1653.
   PubMedGoogle Scholar
• Butler JS, Chan A, Costelha S, et al. Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid. 2016;23(2):109–118.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139(4):431–443.
   PubMed Web of Science ®Google Scholar
• Su Y, Jono H, Torikai M, et al. Antibody therapy for familial amyloidotic polyneuropathy. Amyloid. 2012;19(sup1):45–46.
   PubMed Web of Science ®Google Scholar
• Hosoi A, Su Y, Torikai M, et al. Novel antibody for the treatment of transthyretin amyloidosis. J Biol Chem. 2016;291(48):25096–25105.
   PubMed Web of Science ®Google Scholar
• Ando Y, Ueda M. Antibody therapy for transthyretin-related hereditary amyloid polyneuropathy: another therapeutic option. Amyloid. 2017;24(sup1):113–114.
   PubMed Web of Science ®Google Scholar
• Higaki JN, Chakrabartty A, Galant NJ, et al. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid. 2016;23(2):86–97.
   PubMed Web of Science ®Google Scholar
• Cardoso I, Merlini G, Saraiva MJ. 4 ′-iodo-4′-Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. Faseb J. 2003;17(8):803–809.
   PubMed Web of Science ®Google Scholar
• Macedo B, Batista AR, Ferreira N, et al. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Biochim Biophys Acta. 2008;1782(9):517–522.
   PubMed Web of Science ®Google Scholar
• Cardoso I, Martins D, Ribeiro T, et al. Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010;8:74.
   PubMed Web of Science ®Google Scholar
• Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012;19(sup1):34–36.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J. 2017;7(3):e546.
   PubMedGoogle Scholar
• Doxycycline to upgrade organ response in light chain (AL) amyloidosis trial. 2020 [cited 2020 May 10]. Available at: https://clinicaltrials.gov/ct2/show/study/NCT02207556
   Google Scholar
• A trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac al amyloidosis patients undergoing bortezomib-based therapy. 2020 [cited 2020 May 10]. Available at: https://clinicaltrials.gov/ct2/show/NCT03474458
   Google Scholar
• Giancaterino S, Marcus AU, Dardeu D, et al. Management of arrhythmias in cardiac amyloidosis. J Am Coll Cardiol EP. 2020;6:351–361.
   Google Scholar
• Longhi S, Quarta CC, Milandri A, et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid. 2015;22:147–155.
   PubMed Web of Science ®Google Scholar
• Falk RH, Rubinow A, Cohen AS. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol. 1984;3(1):107–113.
   PubMed Web of Science ®Google Scholar
• Falk RH. Diagnosis and management of the amyloidoses. Circulation. 2005;112:2047–2060.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gertz MA, Kumar SK, et al. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid. 2018;25(2):86–92.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.
   PubMed Web of Science ®Google Scholar
• Mints YY, Doros G, Berk JL, et al. Features of atrial fibrillation in wildtype transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Fail. 2018;5(5):772–779.
   PubMed Web of Science ®Google Scholar
• Palladini G, Malamani G, Cò F, et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol. 2001;24:1228–1233.
   PubMed Web of Science ®Google Scholar
• Sayed RH, Rogers D, Khan F, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J. 2015;36:1098–1105.
   PubMed Web of Science ®Google Scholar
• Kristen AV, Kreusser MM, Blum P, et al. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. J Heart Lung Transplant. 2018 May;37(5):611–618.
   PubMed Web of Science ®Google Scholar